RxDoctor Payments Data

Ruth Rodriguez

Adult Health · Bastrop, TXNPI 1417210840

Payments from drug & device makers

$882in general payments, 2019–2025

Across 29 payments — averaging $30.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$197
  • Inari Medical, Inc.$191
  • E.r. Squibb & Sons, L.L.C.$155
  • Scpharmaceuticals Inc.$125
  • Bayer$88
  • AstraZeneca$30
  • plus $96 from 5 others

What the payments were for

  • Food & beverage$86198%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$882 in reported general payments places this provider in the 65th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$47,534
Medicare patients
302
Services billed
476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban247$184,343
EntrestoSacubitril/Valsartan128$117,380
JardianceEmpagliflozin50$34,070
XareltoRivaroxaban26$32,103
Metoprolol Succinate313$4,843
Carvedilol339$2,738
Atorvastatin Calcium292$2,579
PradaxaDabigatran Etexilate Mesylate12$2,458
Valsartan81$2,274
Potassium Chloride112$1,855
Ranolazine ErRanolazine21$1,606
Rosuvastatin Calcium129$1,577
Torsemide53$1,298
Bumetanide46$1,206
Losartan Potassium135$1,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$197$117,380128 claims
Boehringer IngelheimJardiance, Pradaxa$20$36,52962 claims
Johnson & JohnsonXarelto$15$32,10326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 933 adult health providers in Texas.

Other adult health in Bastrop

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →